San Diego Business Journal

SD HEALTHCARE

Recent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...
Tease photo

Scripps Health Sells Former Hospice Property in Hillcrest for $20 Million

San Diego’s Scripps Health has sold a former hospice facility that it owns in Hillcrest to a Houston-based investment company for $20 million. Camden USA Inc. plans to build a multifamily project on the eight-acre property at 4311 Third Ave., according to CoStar Group and public data.

By Lou Hirsh April 20, 2017 4:57 p.m. share »

Mast Merger Vote Faces Delay

Mast Therapeutics Inc., a local public biotech in the process of being acquired by Austin-based Savara Inc., may have to postpone its meeting to vote on the planned merger.

By Brittany Meiling April 20, 2017 4:47 p.m. share »

IriSys' Deal with National Cancer Institute Doubles to $6 Million

Local drugmaker IriSys LLC announced Thursday that its contract with the National Cancer Institute (NCI) has doubled in value from $3 million to $6 million.

By Brittany Meiling April 20, 2017 3:28 p.m. share »

Ionis Pharmaceuticals to Partner With Chinese Biotech

Carlsbad drugmaker Ionis Pharmaceuticals Inc. has inked a deal with a Chinese biotech that will help Ionis develop and sell its medicines in China.

By Brittany Meiling April 19, 2017 4:25 p.m. share »

Tocagen Inc. Raises $97.8 Million in IPO

San Diego drugmaker Tocagen Inc. ended up raising $97.8 million in an upsized initial public offering this week, making it the largest local IPO since Otonomy’s debut in 2014.

By Brittany Meiling April 19, 2017 2:54 p.m. share »

Drugmaker Tocagen to Raise $85 Million in IPO

San Diego drugmaker Tocagen Inc. plans to raise $85 million in an initial public offering, the company announced Thursday.

By Brittany Meiling April 13, 2017 2:57 p.m. share »

Stock Offering Shakes Investors Confidence in Sorrento Therapeutics

Stock is tanking for local drugmaker Sorrento Therapeutics Inc. following news that it intends to raise $47 million in a public stock offering.

By Brittany Meiling April 13, 2017 2:55 p.m. share »
Tease photo

What's Ex-Google Ventures Exec Up To?

Ex-Google Ventures boss Bill Maris considered launching a $230 million health care fund in late 2016, but ultimately thought better of it. What's he up to?

By Sarah de Crescenzo April 13, 2017 2:52 p.m. share »

Execs Given the ‘Keys’ And Cash for Biotech

Investors have handed the reins of an out-of-state biotech company — along with $40 million in fresh capital — to the former C-suite of San Diego’s short-lived Laguna Pharmaceuticals.

By Brittany Meiling April 13, 2017 1:38 p.m. share »
Tease photo

Persistence Finally Pays Off at Neurocrine Biosciences

The weekend of April 7 was a tense one at the headquarters of Neurocrine Biosciences Inc., where over 300 employees collectively held their breath awaiting word from regulators. A decade-long project was about to make or break the company.

By Brittany Meiling April 13, 2017 1:35 p.m. share »
Tease photo

New Hospital to Meet Challenges, Change

Kaiser Permanente has christened its first new hospital in the San Diego area since 1975, an $850 million facility in Kearny Mesa it says will better integrate care for its 610,000 local members.

By John Cox April 13, 2017 1:31 p.m. share »

Neurocrine's Stock Soars Following FDA Approval of Its Drug Ingrezza

Stock is soaring for San Diego drugmaker Neurocrine Biosciences, which just received a stamp of approval from the U.S. Food and Drug Administration for its lead drug Ingrezza.

By Brittany Meiling April 12, 2017 3:16 p.m. share »

San Diego Behavioral Health Facility Among 6 Being Acquired in $400M Deal

Aurora Behaviorial Health Care San Diego is among six psychiatric hospitals being acquired by Care Capital Properties Inc. in a $400 million deal, the Chicago-based investment company announced.

By Lou Hirsh April 12, 2017 3:14 p.m. share »

Murphy Stepping Down as Organovo CEO; Co. Names Replacement

Keith Murphy, the CEO of San Diego’s 3-D bioprinting company Organovo, is stepping down from his position to “pursue entrepreneurial opportunities,” according to a company statement.

By Brittany Meiling April 11, 2017 4:07 p.m. share »

For Laguna Execs, Failing Fast Led to New $40M Biotech Opportunity

Investors have handed the reins of an out-of-state biotech company — along with $40 million in fresh capital — to the former C-suite of San Diego’s short-lived Laguna Pharmaceuticals.

By Brittany Meiling April 11, 2017 4:06 p.m. share »